VEDOLIZUMAB IS ASSOCIATED WITH STEROID-FREE CLINICAL REMISSION AND DISCONTINUATION-FREE SURVIVAL IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE PROCTITIS

Pauline Lemmens  ¹     João Sabino  ¹     Edouard Louis  ²     Wouter Van Moerkercke  ³     Lieven Pouillon  ⁴     Michaël Somers  ⁵     Harald Peeters  ⁶     Stijn Dr. Vanden Branden  ⁷     Julie Busschaert  ⁸     Filip Baert  ⁹     Anneline Cremer  ¹⁰     Philippe Potvin  ¹¹     Sophie Dewit  ¹²     Arnaud Colard  ¹³     Jo Swinnen  ¹⁴     Guy Lambrecht  ¹⁵     Christophe Claessens  ¹⁶     Barbara Willandt  ¹⁷     Pieter Dewint  ¹⁷     Evi Van Dyck  ¹⁸     Severine Vermeire  ¹⁹     Marc Ferrante  ^19    
1 University Hospital Leuven, Leuven, Belgium
² CHU Liège and Liège University, Liège, Belgium
³ AZ Groeninge, Kortrijk, Belgium
⁴ Imelda Hospital, Bonheiden, Belgium
⁵ University Hospital Antwerp, Antwerp, Belgium
⁶ University Hospital Gent, Gent, Belgium
⁷ Onze Lieve Vrouw Hospital, Aalst, Belgium
⁸ AZ Sint Lucas, Brugge, Belgium
⁹ AZ Delta, Roeselare, Belgium
¹⁰ Erasme University Hospital, Brussels, Belgium
¹¹ AZ Rivierenland, Bornem, Belgium
¹² Noorderhart Maria Hospital, Pelt, Belgium
¹³ Centre Hospitalier Chrétien - Clinique St Joseph, Liège, Belgium
¹⁴ Sint Franciscus Hospital, Heusden-Zolder, Belgium
¹⁵ AZ Damiaan, Oostende, Belgium
¹⁶ AZ Turnhout, Turnhout, Belgium
¹⁷ AZ Sint Jan, Brugge, Belgium
¹⁸ AZ Klina, Brasschaat, Belgium
¹⁹ Catholic University Leuven, Leuven, Belgium

Session
IBD (Posters)

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)